• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

    4/10/25 4:05:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2025 financial results and provide a business update.

    A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

    About Gilead Sciences

    Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

    For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250410465777/en/

    Jacquie Ross, CFA – Investors

    [email protected]

    Get the next $GILD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GILD

    DatePrice TargetRatingAnalyst
    4/22/2025$125.00Overweight
    Cantor Fitzgerald
    3/4/2025$115.00 → $132.00Outperform
    Oppenheimer
    2/18/2025$120.00Hold → Buy
    Deutsche Bank
    2/13/2025$108.00Hold → Buy
    DZ Bank
    1/10/2025$87.00 → $113.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$109.00Buy
    BofA Securities
    11/15/2024$110.00Outperform
    Wolfe Research
    11/14/2024$125.00Buy
    Citigroup
    More analyst ratings

    $GILD
    SEC Filings

    See more
    • SEC Form 13F-HR filed by Gilead Sciences Inc.

      13F-HR - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/13/25 4:15:37 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Gilead Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/8/25 5:26:08 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Gilead Sciences Inc.

      10-Q - GILEAD SCIENCES, INC. (0000882095) (Filer)

      5/7/25 4:32:49 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

      Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625261668/en/ CDK2-directed MGDs are a new type of drug designed to remove CDK2 – a key contributor in tumor growth – rather than just inhibiting its function. Traditional inhibitors o

      6/25/25 7:00:00 AM ET
      $GILD
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

      – Approval Based on Phase 3 PURPOSE 1 and PURPOSE 2 Data that Showed ≥99.9% of Participants Remained HIV Negative on Twice-Yearly Injectable Yeztugo – – Yeztugo, Nearly 20 Years in the Making, Represents a Major Breakthrough in the Fight Against HIV – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP. Data show that

      6/18/25 2:49:00 PM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

      – Long-Term Analysis Shows Similar Safety and Effectiveness Outcomes in Outpatient vs. Inpatient Setting with Positive Impact for Healthcare Systems – Kite, a Gilead Company (NASDAQ:GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) assigned to treatment in an outpatient setting (no planned hospital stay) versus those assigned to an inpatient setting in a hospital. The analysis, based on data collected from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, observed that safety and effectiveness outcomes for people trea

      6/1/25 8:00:00 AM ET
      $GILD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care